A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban

A regiszterben nem jelölt feltételek

• Patients will be entered into this study only if they meet all of the following criteria:
• Age ≥ 20 years at the index date. The index date is defined as the date of the first prescription of label-adherent edoxaban or rivaroxaban.
• Confirmed diagnosis of non-valvular atrial fibrillation (NVAF) prior to or on the index date.
• Most recently measured CrCl rate of 15 to 50 mL/min within 12 months prior to or on the index date.
• Received a prescription for label-adherent dosing (as defined in the protocol) of either: edoxaban (30 mg or 15 mg once daily), or rivaroxaban (15 mg or 10 mg once daily) on the index date.
• Patients with no prescription of any oral anticoagulants (including dabigatran, apixaban, rivaroxaban, edoxaban, and warfarin) for at least 30 days prior to the index date.
  • Patients will be excluded from this study if they meet any of the following criteria:
• Patients who had at least one inpatient or two outpatient records of diagnosis code for any following conditions during the 12-month baseline assessment period prior to the prescription of edoxaban or rivaroxaban:
• End Stage Renal Disease (CrCl < 15 mL/min).
• Venous thromboembolism (pulmonary embolism or deep vein thrombosis).
• Valvular heart disease.